link to research report, page-13

Tharlow,

You are totally inconsistent. In a ChemGenex (CXS) post, you spruik Ceflatonin as a drug with massive potential and above refer to PI-88 as a "specialty drug".

Man! I think you've got the two mixed up! Ceflatonin is targetted at a small portion of the already relatively small (and crowded) Chronic Myeloid Leukaemia market!! Whereas, PI-88 could be applicable to a broad range of common cancers in addition to operable liver cancer.

Please educate yourself dude! Don't try to sabotage this story for others.....But more importantly for you: save some face! 1) get your facts correct; and 2) at least be consistent!!

Nong!